Ipamorelin and CJC-1295 (mod GRF 1-29): A Comparative Review of the Growth-Hormone-Axis Research Literature

Ipamorelin and CJC-1295: two research compounds

Ipamorelin and CJC-1295 are two synthetic peptides that recur together in the growth-hormone (GH) research literature because each acts on a different point of the same neuroendocrine pathway. Ipamorelin is a growth-hormone secretagogue receptor 1a (GHS-R1a) agonist — a ghrelin mimetic, meaning it binds the receptor normally engaged by the gut-and-brain peptide ghrelin. CJC-1295, also referred to as modified GRF 1-29 (mod GRF 1-29) or CJC-1295 without DAC, is described in the literature as a growth-hormone-releasing hormone (GHRH) analogue, a peptide modelled on the first 29 amino acids of endogenous GHRH that stimulates GH release from the pituitary gland.

Because both compounds converge on pituitary GH secretion through complementary receptor systems, they are frequently discussed side by side in reviews of substances prohibited in sport and in analytical (anti-doping) method development. It is important to note at the outset that much of the published record on these two peptides is not clinical efficacy work but rather animal physiology, forensic detection chemistry, and observational accounts of unsanctioned use.

Where the research overlaps

The shared research area that draws these two peptides into the same discussions is growth — specifically the regulation of GH secretion. Ipamorelin has been characterised as acting at GHS-R1a, while CJC-1295 has been characterised as a GHRH analogue; both mechanisms feed into pituitary GH output, which is why they are grouped within the same taxonomy of growth-hormone secretagogues and releasing factors.

This overlap is also visible in the anti-doping and forensic literature, where both compounds appear on the World Anti-Doping Agency Prohibited List and have been the subject of detection-method studies. Analytical work has examined GH-releasing peptide metabolites in human urine (including ipamorelin) and immuno-PCR and LC-MS/MS assays for CJC-1295 in equine plasma. Their co-appearance in these contexts reflects a shared regulatory and analytical framing rather than any single experiment testing them jointly.

How each has been studied

Ipamorelin's most directly cited human research is a phase 2, randomized, double-blind, placebo-controlled proof-of-concept trial in adults undergoing bowel resection, which examined the ghrelin-receptor agonist for postoperative ileus. Its key endpoint was time from first dose to tolerance of a standardized solid meal; the trial reported no significant difference between ipamorelin and placebo on that endpoint or on its secondary analyses, and the authors describe the study as small and enrolling a broad range of underlying conditions. Beyond that human work, ipamorelin has been examined in animal systems: a ferret study assessed whether it and the related agent anamorelin altered cisplatin-induced changes in body weight and feeding, alongside electrically stimulated contractions of isolated ileum, and a study in the cichlid fish Oreochromis mossambicus examined food intake and the hypothalamic-pituitary-testicular axis over 21 days of administration. Analytical work has separately characterised ipamorelin's urinary metabolites in a human volunteer following nasal administration.

CJC-1295 is documented largely through analytical and observational sources rather than controlled clinical trials. Mass-spectrometry work identified the peptide in an unknown pharmaceutical preparation submitted by Norwegian authorities, characterising it as a 29-amino-acid growth-hormone-releasing factor. Assay-development studies in equine plasma describe its maleimidopropionic acid group, which covalently binds plasma proteins so that the resulting conjugate persists in circulation far longer than the unconjugated peptide; those reports also note a reported duration of growth-hormone release exceeding six days in humans after a single administration. A netnographic study analysed online forum discussion of female CJC-1295 use, documenting reported motivations and concerns as social-behavioural data rather than measured outcomes.

Studied together, not combined

The co-appearance of ipamorelin and CJC-1295 in the literature reflects a shared research context — the growth-hormone axis and its regulation, and the analytical and regulatory attention that follows from that — not evidence that they have been tested as a combined intervention or that they act synergistically. None of the cited studies evaluates the two peptides administered together, and no controlled data establish a joint effect.

Readers should treat the two bodies of work as parallel rather than integrated. The ipamorelin record includes limited human trial data alongside animal and metabolite studies; the CJC-1295 record is dominated by forensic detection chemistry and observational accounts of unsanctioned use. Any inference about how the peptides might behave in combination is unsupported by the sources reviewed here, and no dosing, protocol, or comparative ranking can be drawn from them.

What the research does not show

The human evidence identified in this search is limited in scale; larger controlled trials establishing exposure and long-term safety in humans are not yet available.